Rxcurve
HCPCS J2781 · per 1 MG

Inj, pegcetacoplan, 1mg

Products billed under this code include Syfovre.

Payment limit per 1 MG, by effective quarter, 4Q23 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J2781

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Syfovre Apellis Pharmaceuticals, Inc. 73606-0020-01 15 $2,029.005
Syfovre Apellis Pharmaceuticals, Inc. 73606-0020-02 15 $2,029.005

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $135.267 −$13.677 1 MG Inj, pegcetacoplan, 1mg v1, posted September 17, 2026
3Q26 $148.944 +$1.137 1 MG Inj, pegcetacoplan, 1mg v1, posted September 15, 2026
2Q26 $147.807 +$9.758 1 MG Inj, pegcetacoplan, 1mg v1, posted September 15, 2026
1Q26 $138.049 −$1.132 1 MG Inj, pegcetacoplan, 1mg v1, posted September 15, 2026
4Q25 $139.181 −$2.729 1 MG Inj, pegcetacoplan, 1mg v1, posted September 8, 2026
3Q25 $141.91 −$2.079 1 MG Inj, pegcetacoplan, 1mg v1, posted March 10, 2026
2Q25 $143.989 −$2.378 1 MG Inj, pegcetacoplan, 1mg v1, posted March 10, 2026
1Q25 $146.367 −$0.989 1 MG Inj, pegcetacoplan, 1mg v1, posted December 19, 2025
4Q24 $147.356 −$1.714 1 MG Inj, pegcetacoplan, 1mg v1, posted June 11, 2025
3Q24 $149.07 −$0.834 1 MG Inj, pegcetacoplan, 1mg v1, posted June 11, 2025
2Q24 $149.904 −$1.558 1 MG Inj, pegcetacoplan, 1mg v1, posted March 11, 2025
1Q24 $151.462 −$2.059 1 MG Inj, pegcetacoplan, 1mg v1, posted December 19, 2024
4Q23 $153.521 – 1 MG Inj, pegcetacoplan, 1mg v1, posted October 10, 2024

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files